Touchlight awarded ILAP for therapeutic DNA vaccine
Touchlight has been officially awarded an Innovation Passport through Innovative Licensing and Access Pathway (ILAP) for its therapeutic DNA vaccine, a vaccine that targets head and neck squamous cell carcinoma (HNSCC).
ILAP is a novel pathway formed by the MHRA, NICE, SMC, and the AWTTC, supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access. The pathway is designed to ensure that medicines are at the forefront of cutting-edge developments and new technologies. ILAP aims to accelerate the time to market, facilitating patient access to medicine.
Touchlight’s DNA vaccine combines potent cancer antigens with Touchlight’s novel enzymatic DNA vector – doggybone DNA (dbDNA™). Unlike plasmid DNA vectors, dbDNA is a double-stranded, linear, covalently closed molecule that eliminates bacterial sequences, making it an optimal vector for advanced therapies.
Satish Muchakayala, Director of Regulatory Affairs, Touchlight, commented “this is a significant milestone for our TGL-100 doggybone DNA based vaccine for HNSCC. The collective regulatory support from the ILAP committee in designing Target Development Profile (TDP) roadmaps and access to a regulatory support tool kit can enable Touchlight to make further progress with the development of its dbDNA vaccine. Furthermore, with this ILAP designation we can even more effectively support our customers and partners that use doggybone DNA along the regulatory pathway”.
- ENDS -
Touchlight is a privately-owned CDMO based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.
For more information please contact:
|Karen Fallen, Chief Executive Officer|
|Robin Bodicoat, Head of Marketing|
|T: +44 20 8481 9200|